Opening arguments in the first trial of Philadelphia’s Risperdal mass-tort actions began Jan. 23 with attorneys squaring off over whether the drug’s maker failed to warn patients about the risk of male breast growth associated with taking the medication.
The plaintiffs in the roughly 1,257 cases filed in the city’s court system claim that Risperdal, an antipsychotic, causes young males to grow female breast tissue, a condition known as gynecomastia.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
